Koers Neoprobe Corporation Nyse
Aandelen
NEOP
US6405181065
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
|
Omzet 2021 | 532K 491K | Omzet 2022 | 65,65K 60,65K | Marktkapitalisatie | 6,78 mln. 6,26 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -11 mln. -10,16 mln. | Nettowinst (verlies) 2022 | -15 mln. -13,86 mln. | EV/omzet 2021 | 50,2 x |
Nettoliquiditeiten 2021 | 3,48 mln. 3,22 mln. | Nettoschuld 2022 | 440K 406K | EV/omzet 2022 | 110 x |
K/w-verhouding 2021 |
-2,5
x | K/w-verhouding 2022 |
-0,38
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 64,11% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Craig Dais
DFI | Director of Finance/CFO | 58 | 28-07-23 |
Michael Blue
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-21 |
Richard McFerron
LAW | General Counsel | - | 01-04-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Joshua Wilson
BRD | Director/Board Member | 47 | 30-09-22 |
John Scott
BRD | Director/Board Member | 69 | 08-07-21 |
Jill Stefanelli
BRD | Director/Board Member | 46 | 01-06-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,59% | 44,44 mld. | |
+41,02% | 40,03 mld. | |
-10,62% | 37,68 mld. | |
+29,92% | 31,46 mld. | |
-9,23% | 27,29 mld. | |
+12,34% | 26,29 mld. | |
+41,53% | 13,8 mld. | |
+31,49% | 12,46 mld. | |
-7,40% | 11,26 mld. |
- Beurs
- Aandelen
- Koers NAVB
- Koers NEOP